Wisse van Os
Postdoc
- Name
- W. van Os MSc
- Telephone
- 071 5272727
- w.van.os@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0003-1709-4173
Postdoc
- Faculty of Science
- LACDR
- Divisie Systems Pharmacology and Pharmacy
- Wölfl-Duchek M., Os W. van, al Jalali V., Ulrich R., Peter W., Bauer M., Lackner E., Wulkersdorfer B., Marhofer P., Bergmann F., Anselm J., Reiter B., Stimpfl T. & Zeitlinger M. (2025), Cerebrospinal fluid concentrations of ceftaroline and ceftazidime/avibactam in healthy volunteers: pharmacokinetics and probability of target attainment, International Journal of Antimicrobial Agents 66(2): 107512.
- Os W. van, O'Jeanson A., Troisi C., Liu C., Brooks J.T., Hughes J.H., Tong D.M.H. & Keizer R.J. (2025), Machine learning-based model selection and averaging outperform single-model approaches for a priori vancomycin precision dosing, CPT: Pharmacometrics & Systems Pharmacology 14(10): 1650-1660.
- Kok M., Os W. van, Hankemeier T. & Hasselt J.G.C. van (2025), Prolonged anoxic exposure impacts antibiotic sensitivity profiles of Pseudomonas aeruginosa, FEMS Microbiology Letters 372: fnaf066.
- Os W. van, Pham A.D., Eberl S., Minichmayr I.K., Hasselt J.G.C. van & Zeitlinger M. (2024), Integrative model-based comparison of target site-specific antimicrobial effects: a case study with ceftaroline and lefamulin, International Journal of Antimicrobial Agents 63(5): 107148.
- Os W. van & Zeitlinger M. (2024), Cefepime-Taniborbactam in complicated urinary tract infection, The New England Journal of Medicine 390(20): 1937-1939.
- Aranzana-Climent V., Os W. van, Nutman A., Lellouche J., Dishon-Benattar Y., Rakovitsky N., Daikos G. L., Skiada A., Pavleas I., Durante-Mangoni E., Theuretzbacher U., Paul M., Carmeli Y. & Friberg L. E. (2024), Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes, Clinical and Translational Science 17(7): e13870.
- Hosmann A., Moser M.M., Os W. van, Gramms L., Al Jalali V., Sanz Codina M., Plöchl W., Lier C., Kees F., Dorn C., Rössler K., Reinprecht A. & Zeitlinger M. (2024), Linezolid brain penetration in neurointensive care patients, Journal of Antimicrobial Chemotherapy 79(3): 669-677.
- Os W. van, Nussbaumer-Pröll A., Pham A.D., Wijnant G.J., Ngougni Pokem P., Bambeke F. Van, Hasselt J.G.C. van & Zeitlinger M. (2024), Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections, Journal of Antimicrobial Chemotherapy 79(10): 2484-2492.
- Bergmann F., Wölfl-Duchek M., Jorda A., Al Jalali V., Leutzendorff A., Sanz-Codina M., Gompelmann D., Trimmel K., Weber M., Eberl S., Os W. van, Minichmayr I.K., Reiter B., Stimpfl T., Idzko M. & Zeitlinger M. (2024), Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions, Journal of Antimicrobial Chemotherapy 79(5): 1169-1175.
- Grafeneder J., Os W. van, Minichmayr I.K., Kovacevic Miljevic K.D., Reiter B., Säemann M.D., Machold-Fabrizii V., Ahmed A., Spechtl P., Omic H., Sunder-Plaßmann R., Jilma B., Schoergenhofer C. & Eskandary F. (2024), Prospective trial on the pharmacokinetics of clopidogrel in hemodialysis patients, Kidney International Reports 9(10): 2970-2980.
- Os W. van & Zeitlinger M. (2024), Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections, Journal of Antimicrobial Chemotherapy 79(2): 443-446.
- Sanz-Codina M., Os W. van, Pham A.D., Jorda A., Wölfl-Duchek M., Bergmann F., Lackner E., Lier C., Hasselt J.G.C. van, Minichmayr I.K., Dorn C., Zeitlinger M. & Al Jalali V. (2024), Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers, Journal of Antimicrobial Chemotherapy 79(12): 3281-3288.
- Os W. van, Wulkersdorfer B., Eberl S., Oesterreicher Z., Schwabl P., Reiberger T., Paternostro R., Weber M, Willinger B. & Zeitlinger M. (2023), Bacterial growth and ceftriaxone activity in individual ascitic fluids in an in vitro model of spontaneous bacterial peritonitis, Frontiers in Pharmacology 14: 1124821.
- Sanz-Codina M., Wicha S.G. Wulkersdorfer B., Al Jalali V., Os W. van, Vossen M. G., Bauer M., Lackner E., Dorn C. & Zeitlinger M. (2023), Comparison of ultrafiltration and microdialysis for ceftriaxone protein-binding determination, Journal of Antimicrobial Chemotherapy 78(2): 380-388.
- Al Jalali V., Matzneller P., Pham A.D., Os W. van, Wölfl-Duchek M., Sanz-Codina M., Vychytil A., Reiter B., Stimpfl T. & Zeitlinger M. (2023), Plasma and intraperitoneal pharmacokinetics of ceftazidime/avibactam in peritoneal dialysis patients, Clinical Microbiology and Infection 29(9): 1196.e1-1196.e7.
- Os W. van & Zeitlinger M. (2021), Predicting antimicrobial activity at the target site: pharmacokinetic/pharmacodynamic indices versus time-kill approaches, Antibiotics 10(12): 1485.
- Aulin L.B.S., Koumans C.I.M., Haakman Y., Os W. van, Kraakman M.E.M., Gooskens J., Smits W.K., Liakopoulos A. & Hasselt J.G.C. van (2021), Distinct evolution of colistin resistance associated with experimental resistance evolution models in Klebsiella pneumoniae, Journal of Antimicrobial Chemotherapy 76(2): 533-535.
- Poppe M., Clodi C., Schriefl C., Mueller M., Sunder-Plaßmann R., Reiter B., Rechenmacher M., Os W. van., Hasselt J.G.C., Holzer M., Herkner H., Schwameis M., Jilma B., Schoergenhofer C. & Weiser C. (2021), Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - a probe drug of CYP2C19 metabolism, Biomedicine & Pharmacotherapy 146: 112573.